focus -WSS

focus

author：knowledge 2025-09-29 14:00:34 - browse：68979

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

hotspot

WSS

Deposition: Sackler embraced plan to conceal OxyContin’s strength

HIPAA doesn't protect reproductive records from prosecutors

Pharma companies must ensure equitable access to obesity drugs

Pharma companies must ensure equitable access to obesity drugs

CDC backtracks, saying fully vaccinated people can go maskless indoors

Cigna wins case to block Amy Bricker's move to CVS

explore

focus

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Health care court cases: Humana, Sutter, Novant

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

In new study, freeze

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

The cancer drug shortage isn’t new — and neither are the solutions

Review: 'Barbie' will hit you like a shot in the heart

Hollywood unions extend contract negotiations for actors

Readers discuss the intersection of pregnancy and addiction

hotspot

New rules on organ donation and transplantation 'will bring chaos'

In new study, freeze

STAT Virtual Event: ASCO Recap, Live!

Marvel Studios reveals new trailer for 'The Marvels': Watch here

Report captures long Covid’s disabling effects and policy challenges

Medical device trials still don't enroll enough women, study finds

Wikipedia

explore

hotspot

Wikipedia